SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending amid speculation around potential connections to Elon Musk's Grok AI. The community is also excited about the project's fundamentals, including its zero-tax setup, and a potential listing on Binance. Many participants are expressing bullish sentiment, using terms like "WAGMI" and "To The Moon".

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community celebrates its joke-inspired roots and long-term presence on the Solana blockchain. Many are drawn to its dedicated community, locked liquidity, and association with the popular "What's UpDog?" meme, while others highlight its potential within the broader meme coin landscape.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending amidst community enthusiasm, fueled by its meme-centric nature and comparisons to other successful meme coins. Community members are actively encouraging each other to 'RAGE HARDER' and expressing strong bullish sentiment, while also highlighting growing community and potential for significant gains. The coin is also getting attention from influencers.

Pump.fun

PUMP.X is trending as community members discuss its potential within the Solana ecosystem, particularly alongside tokens like WAGMI. Bullish sentiment seems to be fueled by the platform's mechanics around token buybacks and creator rewards. Some traders are closely watching key support and resistance levels, anticipating potential breakouts.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending as the community rallies around $UPDOG, a Solana-based meme coin exclusively listed on Jupiter's strict list, driving discussions about loading up on the token. The focus is on swapping $SOL for $UPDOG on Jupiter, with community members highlighting the project's long-term development and strong community vibes. Amidst the broader meme coin season, UpDog's unique listing on Jupiter is a key catalyst.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its bullish technical setup and potential for an upside breakout, fueled by recent news of the acquisition of anti-coagulant assets. The community highlights the momentum and strong buyer confidence, while also noting the healthcare technology niche and upcoming milestones for their drug Tecarfarin. Some are watching for volume to confirm the move, and analysts are noting high price targets for the stock.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending due to topline results from its Phase 2b study, with community members eagerly awaiting further details. Some speculate on the potential for significant gains depending on the results, especially related to viral load reduction. The company's work on zelicapavir, an oral RSV N-protein inhibitor, is also drawing attention, particularly its potential in the adult RSV therapeutics market.

Codatta

Codatta ($XNY.X) is trending amid discussions about its on-chain fingerprint verification launch and potential applications of its AI/data utility. The community is analyzing its chart patterns, with some pointing to bullish setups and expecting new highs, while others are watching key support levels for potential entry points. Sentiment is mixed, with some expressing excitement about its potential and others remaining cautious.

FFFFFFFFFFFFFUUUUUUUUUUUUUUUU

$RAGEGUY.X is trending as the community discusses its recent price action and potential for further gains, with some users reporting significant increases. The conversation highlights community excitement and speculation around potential 'V-shape recovery coding'. Mentions of related tokens like $UPDOG.X and $401JK.X are also contributing to the increased interest.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV.X) is trending as the community discusses its strong chart and potential for another leg up, with some highlighting treasury loop mechanisms like airdrops and buybacks. The community also notes ongoing consolidation and recent upward movement, with some suggesting potential buybacks are underway. Furthermore, the community is discussing the partnership of Synthetix and Derive to build derivatives on ETH L1.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SurgePays, Inc. (SURG) Reports Q2 Loss, Lags Revenue Estimates

SurgePays, Inc. (SURG) delivered earnings and revenue surprises of -16.13% and -32.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Porch Group, Inc. (PRCH) Reports Break-Even Earnings for Q2

Porch Group (PRCH) delivered earnings and revenue surprises of +100.00% and +10.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue Estimates

Shares of nano-cap SurgePays, Inc. (SURG) jumped on Wednesday after the telecom and fintech company issued an upbeat outlook after announcing subpar annual results.The Barlett, Tennessee-based company reported a loss of $2.39 per share and revenue of $60.88 million for the year ended Dec. 31. This compares to the year-ago earnings per share (EPS) of $1.45 and revenue of $137.14 million.&nbsp;SurgePays blamed the predicament on the end of the federally funded Affordable Connectivity Program (ACP).The ACP is a U.S. government-sponsored program administered by the Federal Communications Commission (FCC) that provides affordable internet access to low-income households. The program stopped accepting applications in the first half of 2024, with April 2024 being the last fully-funded month.Even so, the company&nbsp;was upbeat about&nbsp;its outlook. “However, strategic investments made during this transition — including AT&amp;T integration, POS growth, and the development of our MVNE platform — have built the foundation for 2025's goal to return to growth and profitability,” it said.&nbsp;Brian Cox, Chairman and CEO, said, "We built the infrastructure. Now we are scaling. With AT&amp;T integration complete and LinkUp Mobile launching nationally, SurgePays is positioned for the most aggressive revenue growth phase in our history."LinkUp Mobile is the company’s retail prepaid wireless brand.Looking ahead, the company expects&nbsp;over $200 million in revenue over the next 12 months and positive cash flow from operations before the end of 2025, following the successful integration and official launch with AT&amp;T.&nbsp;The revenue guidance for the year is markedly above the Finchat-compiled consensus of $95.11 million.&nbsp;On Stocktwits, retail sentiment toward SurgePays stock stayed ‘extremely bullish’ (100/100) and the message volume spurted to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:637/137;" src="https://news.stocktwits-cdn.com/surg_sentiment_png_b7d7d166fb.webp" alt="surg-sentiment.png" width="637" height="137"><figcaption>SURG sentiment and message volume March 26, as of 12:54 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>A bullish watcher positioned for a multi-day run and predicted a move to $3 on Thursday.<stembedurl>https://stocktwits.com/Harunkaraca/message/609306748</stembedurl>Another user attributed his bullish sentiment to the moving average convergence divergence (MACD) indicator crossing over.<stembedurl>https://stocktwits.com/BananaExpress15/message/609287406</stembedurl><a href="https://stocktwits.com/symbol/SURG">SurgePays stock</a> soared by over 54% to $2.13 on Wednesday afternoon. The stock is down about 22.5% this year. If the gains are sustained, the stock is on track to finish with the biggest one-day gain in four years.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/playtika-receives-double-upgrade-from-bofa/chJbRWxRb3l">Playtika Stock On Track To Record Biggest Single-Day Gain Ever After BofA’s Double Upgrade: Retail’s Exuberant</a>

Rising stock market chart on a trading board background.

SurgePays Stock Surges As Strong Guidance Overshadows FY24 Underperformance: Retail Anticipates Multi-Day Run  

 CEO Brian Cox said the company is positioned for the most aggressive revenue growth phase in its history.

Equity

 CEO Brian Cox said the company is positioned for the most aggressive revenue growth phase in its history.


SurgePays Appoints Allison Seyler as Vice President of Sales to Drive Growth Across Direct, Partner and Reseller Channels

SurgePays Appoints Allison Seyler as Vice President of Sales to Drive Growth Across Direct, Partner and Reseller Channels SurgePays Appoints Allison Seyler as Vice President of Sales to Drive Growth...

SurgePays Appoints Mark Garner as Executive Vice President

SurgePays Appoints Mark Garner as Executive Vice President SurgePays Appoints Mark Garner as Executive Vice President PR Newswire BARTLETT, Tenn., Jan. 24, 2025 Industry veteran brings nearly three...

SurgePays' ClearLine Marketing Platform Integrates with Clover Point of Sale System

SurgePays' ClearLine Marketing Platform Integrates with Clover Point of Sale System SurgePays' ClearLine Marketing Platform Integrates with Clover Point of Sale System PR Newswire BARTLETT, Tenn...

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

SurgePays Integrates its ClearLine Marketing Platform with PAX Smart Payment Terminals

SurgePays Integrates its ClearLine Marketing Platform with PAX Smart Payment Terminals SurgePays Integrates its ClearLine Marketing Platform with PAX Smart Payment Terminals PR Newswire BARTLETT...

SurgePays Establishes Strategic Agreement with ATandT

SurgePays Establishes Strategic Agreement with AT&T SurgePays Establishes Strategic Agreement with AT&T PR Newswire BARTLETT, Tenn., Nov. 21, 2024 Agreement with AT&T Enables SurgePays to Offer Full...

SurgePays, Inc. operates as a technology-driven company, which focuses on building a supply chain software platform as an alternative to traditional wholesale supply chain distribution models. It offers goods and services direct to convenience stores, bodegas, minimarts, tiendas and other corner stores, providing goods and services primarily to the underbanked community. The company was founded on August 18, 2006 and is headquartered in Bartlett, TN.

Surgepays Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$2.85
Prev Close	$2.86
Open	$2.81
Dividend Yield	0.00%
50-Day Moving Average	$2.76
Beta	0.89
Avg. Volume	173,535.24
PE Ratio	-1.16

52-Week High	$3.47
52-Week Low	$1.05
Market Capitalization	$58.23M
EPS (Annual)	-$2.39
Price to Book	484.69
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

SURG
Surgepays Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SURG News

SURG Surgepays Inc